PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours

PATRIOT：一项 I 期研究，旨在评估一种特定的共济失调毛细血管扩张症和 Rad3 相关 (ATR) 抑制剂 (AZD6738) 作为单药以及与姑息性放射疗法联合用于实体瘤患者的耐受性、安全性和生物学效应。

阅读：2
作者：Dillon,M T,Boylan,Z,Smith,D,Guevara,J,Mohammed,K,Peckitt,C,Saunders,M,Banerji,U,Clack,G,Smith,S A,Spicer,J F,Forster,M D,Harrington,K J
期刊：Clinical and Translational Radiation Oncology影响因子：2.700
时间：2018起止号：2018 Aug;12:16-20
doi：10.1016/j.ctro.2018.06.001靶点： TRIO、ATR

Abstract

PATRIOT is a phase I study of the ATR inhibitor, AZD6738, as monotherapy, and in combination with palliative radiotherapy. Here, we describe the protocol for this study, which opened in 2014 and is currently recruiting and comprises dose escalation of both drug and radiotherapy, and expansion cohorts.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用；引用内容仅为补充信息，不代表本站立场。

2、若认为本页面引用内容涉及侵权，请及时与本站联系，我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容，需注明“来源：[生知库]”并获得授权；使用引用内容的，需自行联系原作者获得许可。

4、投稿及合作请联系：info@biocloudy.com。